GLP-1 / metabolic
Tirzepatide
Used for weight reduction, appetite and glycaemic control (dual GIP/GLP-1 agonist).
Also known as: LY3298176
What it is used for
- Body-weight management / obesity (where registered)
- Type 2 diabetes (local indications)
- Appetite and glycaemic control
- Cardiometabolic markers in research
Disclaimer — Research Use Only
Materials listed on this website are supplied for laboratory research only (Research Use Only). They are not intended for human consumption.
Quick Facts
- Category
- GLP-1 / metabolic
- Research status
- Approved in selected indications (outside MarcinLabs)
- Strength (illustration)
- 15 mg
- Price-list variants
- 5mg · 10mg · 15mg · 20mg
- Also known as
- LY3298176
Overview
Tirzepatide is a peptide studied and used in selected metabolic indications in some countries — mainly body weight, appetite and glycaemia. On MarcinLabs we discuss mechanisms and literature educationally, without treatment recommendations.
What it is used for
Community and research context — not a medical indication or treatment advice.
- Body-weight management / obesity (where registered)
- Type 2 diabetes (local indications)
- Appetite and glycaemic control
- Cardiometabolic markers in research
Tirzepatide is one of the best-known metabolic peptides: in many countries it has approved indications related to type 2 diabetes and/or obesity (depending on product and regulator). In community practice it is discussed for weight reduction, appetite control and glucose markers. On MarcinLabs we keep a clear line: describing indications and mechanism ≠ recommending that you self-start tirzepatide.
For people comparing metabolic options in the literature and following documentation — treatment decisions need a treating clinician.
How it works
It is a dual agonist of GIP and GLP-1 receptors. Versus a “pure” GLP-1 (e.g. semaglutide) it adds a GIP component, which trials linked to strong effects on body weight and glycaemia. The mechanism includes satiety, slower gastric emptying and metabolic signalling in pancreas and peripheral tissues — a literature simplification, not a full pharmacology lecture.
It acts as an agonist of GIP and GLP-1 receptors, influencing incretin signalling linked to appetite, glycaemia and energy metabolism in research models and clinical studies.
How it is used (research context)
From protocols and documentation — not a dosing guide.
In approved indications it is usually a once-weekly subcutaneous injection per the label and clinician judgement (dose escalation, monitoring). Research forms may look different (lyophilisate). Do not copy forum schedules — populations, contraindications and interactions differ.
Key takeaways
- Often compared with semaglutide for weight-effect strength
- Needs assessment of contraindications (history, other drugs)
- GI side effects are common early on
- MarcinLabs does not run therapy or prescriptions
Who this content is for: For people comparing metabolic options in the literature and following documentation — treatment decisions need a treating clinician.
Current research
Approved in selected indications (outside MarcinLabs)
In selected jurisdictions tirzepatide has approved indications (e.g. type 2 diabetes / obesity — depending on local decisions). MarcinLabs is not a source of therapeutic decisions.
Contexts from literature — not therapeutic indications.
- Glycaemic control
- Body weight and composition
- Cardiometabolic markers
- Comparisons with GLP-1 agonists
Potential side effects
- Gastrointestinal discomfort
- Hypoglycaemia risk in combinations with some antidiabetic drugs (clinical context)
- Possible effects related to rapid body-composition research
- Contraindications and warnings depend on the label and clinician judgement
Frequently asked questions
Does MarcinLabs sell tirzepatide?
Related scientific papers
Tirzepatide once weekly for the treatment of obesity
Jastreboff et al. · 2022 · NEJM
PubMed / source →Related YouTube videos
YouTube HubNo matching videos — see the YouTube Hub.
Related MarcinLabs articles
ResearchNo direct notes — see the Research Hub.
Related peptides
Retatrutide
Used in research on substantial body-composition research, appetite and metabolism (GIP/GLP-1/glucagon triple agonist).
Semaglutide
Used in research and clinic for body weight, appetite and type 2 diabetes (GLP-1 agonist).
Cagrilintide
Used in research on satiety, appetite and body weight (amylin analogue; often with GLP-1).
In the research library
Tirzepatide